drugset
drugset / Trial / NCT00544960

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

NCT00544960 ↗

Phase 2 Completed 106 enrolled Ascenta Therapeutics
Non-randomizedCrossoverQuadruple-blindTreatment

Summary

This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung cancer

Timeline

Start
2007-09
Primary completion
2008-11
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AT-101 Small molecule 30 mg —
Background Docetaxel Small molecule 75 mg/m2 —

Indications

non-small cell lung carcinoma